Harvard Program in Therapeutic Science, Harvard Medical School Laboratory of Systems Pharmacology, Boston, Massachusetts.
Renal Division, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
J Am Soc Nephrol. 2018 Dec;29(12):2820-2833. doi: 10.1681/ASN.2018040392. Epub 2018 Oct 25.
The death of epithelial cells in the proximal tubules is thought to be the primary cause of AKI, but epithelial cells that survive kidney injury have a remarkable ability to proliferate. Because proximal tubular epithelial cells play a predominant role in kidney regeneration after damage, a potential approach to treat AKI is to discover regenerative therapeutics capable of stimulating proliferation of these cells.
We conducted a high-throughput phenotypic screen using 1902 biologically active compounds to identify new molecules that promote proliferation of primary human proximal tubular epithelial cells .
The primary screen identified 129 compounds that stimulated tubular epithelial cell proliferation. A secondary screen against these compounds over a range of four doses confirmed that eight resulted in a significant increase in cell number and incorporation of the modified thymidine analog EdU (indicating actively proliferating cells), compared with control conditions. These eight compounds also stimulated tubular cell proliferation after damage induced by hypoxia, cadmium chloride, cyclosporin A, or polymyxin B. ID-8, an inhibitor of dual-specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A), was the top candidate identified as having a robust proproliferative effect in two-dimensional culture models as well as a microphysiologic, three-dimensional cell culture system. Target engagement and genetic knockdown studies and RNA sequencing confirmed binding of ID-8 to DYRK1A and upregulation of cyclins and other cell cycle regulators, leading to epithelial cell proliferation.
We have identified a potential first-in-class compound that stimulates human kidney tubular epithelial cell proliferation after acute damage .
近端肾小管上皮细胞的死亡被认为是急性肾损伤(AKI)的主要原因,但在肾损伤中存活的上皮细胞具有显著的增殖能力。由于近端肾小管上皮细胞在损伤后对肾脏再生起着主要作用,因此一种潜在的治疗 AKI 的方法是发现能够刺激这些细胞增殖的再生治疗药物。
我们使用 1902 种生物活性化合物进行了高通量表型筛选,以鉴定能够促进原代人近端肾小管上皮细胞增殖的新分子。
初级筛选鉴定出 129 种刺激肾小管上皮细胞增殖的化合物。对这些化合物在四个剂量范围内的二次筛选证实,与对照条件相比,有 8 种化合物导致细胞数量显著增加,并且掺入了修饰的胸苷类似物 EdU(表示正在活跃增殖的细胞)。在缺氧、氯化镉、环孢素 A 或多粘菌素 B 诱导的损伤后,这 8 种化合物也刺激了管状细胞的增殖。ID-8,一种双特异性酪氨酸磷酸化调节激酶 1A(DYRK1A)抑制剂,是在二维培养模型以及微生理三维细胞培养系统中具有强大促增殖作用的首选候选药物。靶标结合和基因敲低研究以及 RNA 测序证实 ID-8 与 DYRK1A 结合,并上调细胞周期蛋白和其他细胞周期调节剂,导致上皮细胞增殖。
我们已经确定了一种潜在的新型化合物,它可以在急性损伤后刺激人肾小管上皮细胞的增殖。